Logo image of ACXP

ACURX PHARMACEUTICALS INC (ACXP) Stock Overview

NASDAQ:ACXP - US00510M1045 - Common Stock

4.715 USD
+0.17 (+3.63%)
Last: 8/22/2025, 8:00:00 PM

ACXP Key Statistics, Chart & Performance

Key Statistics
52 Week High46.6
52 Week Low3.8
Market Cap7.45M
Shares1.58M
Float1.46M
Yearly DividendN/A
Dividend YieldN/A
EPS(TTM)-4.42
PEN/A
Fwd PEN/A
Earnings (Next)11-11 2025-11-11
IPO06-25 2021-06-25
Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryBiotechnology


ACXP short term performance overview.The bars show the price performance of ACXP in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 -20 -40 -60

ACXP long term performance overview.The bars show the price performance of ACXP in the last 1, 2 and 3 years. 1 year 2 years 3 years -20 -40 -60 -80

The current stock price of ACXP is 4.715 USD. In the past month the price decreased by -41.92%. In the past year, price decreased by -89.61%.

ACURX PHARMACEUTICALS INC / ACXP Daily stock chart

ACXP Competitors/Peers

The largest stocks on the US markets in the "Biotechnology" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
ABBV ABBVIE INC 19.89 372.04B
AMGN AMGEN INC 13.47 158.13B
GILD GILEAD SCIENCES INC 14.83 142.41B
VRTX VERTEX PHARMACEUTICALS INC 23.32 101.30B
REGN REGENERON PHARMACEUTICALS 12.92 62.48B
ALNY ALNYLAM PHARMACEUTICALS INC N/A 59.56B
ARGX ARGENX SE - ADR 71.2 40.39B
ONC BEONE MEDICINES LTD-ADR 6.35 37.29B
INSM INSMED INC N/A 27.88B
BNTX BIONTECH SE-ADR N/A 26.66B
NTRA NATERA INC N/A 22.73B
BIIB BIOGEN INC 8.7 20.42B

About ACXP

Company Profile

ACXP logo image Acurx Pharmaceuticals, Inc. operates as a clinical stage biopharmaceutical company, which engages in developing new antibiotics for infections caused by bacteria listed as priority pathogens. The company is headquartered in Staten Island, New York and currently employs 4 full-time employees. The company went IPO on 2021-06-25. The company develops antibiotic candidates with a Gram-positive selective spectrum (GPSS) that block the active site of the Gram positive specific bacterial enzyme deoxyribonucleic acid (DNA) polymerase IIIC (pol IIIC), inhibiting DNA replication and leading to Gram-positive bacterial cell death. Its research and development (R&D) pipeline include antibiotic product candidates that target Gram-positive bacteria, including Clostridioides difficile (C. difficile), methicillin-resistant Staphylococcus aureus (MRSA), vancomycin resistant Enterococcus (VRE), drug-resistant Streptococcus pneumoniae (DRSP) and B. anthracis (anthrax; a Bioterrorism Category A Threat-Level pathogen). Its lead antibiotic candidate, ibezapolstat targets the pol IIIC enzyme.

Company Info

ACURX PHARMACEUTICALS INC

259 Liberty Avenue

Staten Island NEW YORK US

CEO: David P. Luci

Employees: 4

ACXP Company Website

ACXP Investor Relations

Phone: 19175331469

ACURX PHARMACEUTICALS INC / ACXP FAQ

What is the stock price of ACURX PHARMACEUTICALS INC today?

The current stock price of ACXP is 4.715 USD. The price increased by 3.63% in the last trading session.


What is the ticker symbol for ACURX PHARMACEUTICALS INC stock?

The exchange symbol of ACURX PHARMACEUTICALS INC is ACXP and it is listed on the Nasdaq exchange.


On which exchange is ACXP stock listed?

ACXP stock is listed on the Nasdaq exchange.


What is the price forecast or stock price prediction for ACURX PHARMACEUTICALS INC stock?

9 analysts have analysed ACXP and the average price target is 62.93 USD. This implies a price increase of 1234.76% is expected in the next year compared to the current price of 4.715. Check the ACURX PHARMACEUTICALS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.


What is ACURX PHARMACEUTICALS INC worth?

ACURX PHARMACEUTICALS INC (ACXP) has a market capitalization of 7.45M USD. This makes ACXP a Nano Cap stock.


How many employees does ACURX PHARMACEUTICALS INC have?

ACURX PHARMACEUTICALS INC (ACXP) currently has 4 employees.


What are the support and resistance levels for ACURX PHARMACEUTICALS INC (ACXP) stock?

ACURX PHARMACEUTICALS INC (ACXP) has a resistance level at 5.12. Check the full technical report for a detailed analysis of ACXP support and resistance levels.


Should I buy ACURX PHARMACEUTICALS INC (ACXP) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does ACURX PHARMACEUTICALS INC (ACXP) stock pay dividends?

ACXP does not pay a dividend.


When does ACURX PHARMACEUTICALS INC (ACXP) report earnings?

ACURX PHARMACEUTICALS INC (ACXP) will report earnings on 2025-11-11.


What is the Price/Earnings (PE) ratio of ACURX PHARMACEUTICALS INC (ACXP)?

ACURX PHARMACEUTICALS INC (ACXP) does not have a PE ratio as the earnings reported over the last twelve months were negative (-4.42).


ACXP Technical Analysis


Chartmill TA Rating
Chartmill Setup Rating

ACXP Fundamental Analysis

ChartMill assigns a fundamental rating of 1 / 10 to ACXP. ACXP scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

ACXP Financial Highlights

Over the last trailing twelve months ACXP reported a non-GAAP Earnings per Share(EPS) of -4.42. The EPS decreased by -284.35% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -162.38%
ROE -280.37%
Debt/Equity 0
Chartmill High Growth Momentum
EPS Q2Q%-626.92%
Sales Q2Q%N/A
EPS 1Y (TTM)-284.35%
Revenue 1Y (TTM)N/A

ACXP Forecast & Estimates

9 analysts have analysed ACXP and the average price target is 62.93 USD. This implies a price increase of 1234.76% is expected in the next year compared to the current price of 4.715.


Analysts
Analysts82.22
Price Target62.93 (1234.68%)
EPS Next Y-1131.03%
Revenue Next YearN/A

ACXP Ownership

Ownership
Inst Owners15.43%
Ins Owners10.95%
Short Float %N/A
Short Ratio0.07